Skip to main content
SpringerLink
Log in

TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis

  • Original Paper
  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

TR-644 is a novel combretastatin A-4 (CA-4) analogue endowed with potent microtubule depolymerizing activity superior to that of the lead compound and it also has high affinity to colchicines binding site of tubulin. We tested TR-644 anti-angiogenic effects in human umbilical endothelial cells (HUVEC). It showed no significant effects on the growth of HUVEC cells at concentrations below 1,000 nM, but at much lower concentrations (10–100 nM) it induced inhibition of capillary tube formation, inhibition of endothelial cell migration and affected endothelial cell morphology as demonstrated by the disruption of the microtubule network. TR-644 also increased permeability of HUVEC cells in a time dependent manner. The molecular mechanism for the anti-vascular activity of TR-644 was investigated in detail. TR-644 caused G2/M arrest in endothelial cells and this effect correlated with downregulation of the expression of Cdc25C and Cdc2Tyr15. Moreover TR-644 inhibited VEGF-induced phosphorylation of VE-cadherin but did not prevent the VEGF-induced phosphorylation of FAK. In chick chorioallantoic membrane in vivo assay, TR-644 (0.1–1.0 pmol/egg) efficiently counteracted the strong angiogenic response induced by FGF. Also CA-4, used as reference compound, caused an antagonistic effect, but in contrast, it induced per se, a remarkable angiogenic response probably due to an inflammatory reaction in the site of treatment. In a mice allogenic tumor model, immunohistochemical staining of tumors with anti-CD31 antibody showed that TR-644 significantly reduced the number of vessel, after 24 h from the administration of a single dose (30 mg/Kg).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265

    Article  PubMed  CAS  Google Scholar 

  2. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790–803

    Article  PubMed  CAS  Google Scholar 

  3. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumor blood vessel. Nat Rev Cancer 5:423–435

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594–2601

    Article  PubMed  CAS  Google Scholar 

  5. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318–1327

    Article  PubMed  CAS  Google Scholar 

  6. Gaukroger K, Hadfield JA, Lawrence NJ, Nlan S, McGown AT (2003) Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org Biomol Chem 1:3033–3037

    Article  PubMed  CAS  Google Scholar 

  7. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006) Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:3033–3044

    Article  PubMed  CAS  Google Scholar 

  8. Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, Gherke L, Credo RB, Hui YH, Marsh K, Warner R, Lee JY, Zielinski-Mozng N, Frost D, Rosenberg SH, Sham HL (2002) Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 45:1697–1711

    Article  PubMed  CAS  Google Scholar 

  9. Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T (2010) 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cis platin resistant germ cell tumor model. J Med Chem 53:6595–6602

    Article  PubMed  CAS  Google Scholar 

  10. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihai Y, Suga Y, Morinaga Y, Akiyama Y, Tsuji T (1988) Synthesis and antitumor activity of cis-restricted combretastatins 5-membered heterocyclic analogues. Bioorg Med Chem Lett 8:3153–3158

    Article  Google Scholar 

  11. Tron GC, Pagliai F, Del Grosso E, Genazzani AA, Sorba G (2005) Synthesis and cytotoxic evaluation of combretafurazans. J Med Chem 48:3260–3268

    Article  PubMed  CAS  Google Scholar 

  12. Liu T, Dong X, Xue N, Wu R, He Q, Yang B, Hu Y (2009) Synthesis and biological evaluation of 3,4-biaryl-5-aminoisoxazole derivatives. Bioorg Med Chem 17:6279–6285

    Article  PubMed  CAS  Google Scholar 

  13. Wu M, Li W, Yang C, Chen D, Ding J, Chen Y, Lin L, Xie Y (2007) Synthesis and activity of combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents. Bioorg Med Chem Lett 17:869–873

    Article  PubMed  CAS  Google Scholar 

  14. Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez-Cara C, Carrion MD, Brancale A, Hamel E, Chen L, Bortolozzi R, Basso G, Viola G (2010) Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogs. J Med Chem 53:4248–4258

    Article  PubMed  CAS  Google Scholar 

  15. Romagnoli R, Baraldi PG, Brancale A, Ricci A, Hamel E, Bortolozzi R, Basso G, Viola G (2011) Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J Med Chem 54:5144–5153

    Article  PubMed  CAS  Google Scholar 

  16. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experentia 45:209–211

    Article  CAS  Google Scholar 

  17. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299–309

    PubMed  CAS  Google Scholar 

  18. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, Hogan F (1985) Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 38:1666–1672

    Article  Google Scholar 

  19. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F (2003) IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol 171:3725–3733

    PubMed  CAS  Google Scholar 

  20. Basili S, Basso G, Faccio A, Granzhan A, Ihmels H, Moro S, Viola G (2008) Diazoniapolycyclic ions inhibit activity of topoisomerase I and growth of certain tumor cell lines. ChemMedChem 3:1671–1676

    Article  PubMed  CAS  Google Scholar 

  21. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329–333

    Article  PubMed  CAS  Google Scholar 

  22. Guidolin D, Vacca A, Nussdorfer GG, Ribatti D (2004) A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res 67:117–124

    Article  PubMed  CAS  Google Scholar 

  23. Viola G, Fortunato E, Cecconet L, Del Giudice L, Dall’Acqua F, Basso G (2008) Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 227:84–96

    Article  PubMed  CAS  Google Scholar 

  24. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M (2011) Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 31:e116–e127

    Article  PubMed  CAS  Google Scholar 

  25. Dejana E, Giampietro C (2012) Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 19:218–223

    Article  PubMed  CAS  Google Scholar 

  26. Vittet D, Buchou T, Schweitzer A, Dejana E, Huber P (1997) Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci USA 94:6273–6278

    Article  PubMed  CAS  Google Scholar 

  27. Feraud O, Cao Y, Vittet D (2001) Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab Invest 81:1669–1681

    Article  PubMed  CAS  Google Scholar 

  28. Dejana E, Orsenigo F, Lampugnani MG (2008) The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121:2115–2122

    Article  PubMed  CAS  Google Scholar 

  29. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992–3006

    Article  PubMed  CAS  Google Scholar 

  30. Bogatcheva NV, Verin AD (2008) The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res 76:202–207

    Article  PubMed  CAS  Google Scholar 

  31. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68

    Article  PubMed  CAS  Google Scholar 

  32. Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC (2011) VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell 22:2766–2776

    Article  PubMed  CAS  Google Scholar 

  33. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD (2012) VEGF-induced vascular permeability is mediated by FAK. Dev Cell 22:146–157

    Article  PubMed  CAS  Google Scholar 

  34. Andrés G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcamí A, Presta M (2009) A pro-inflammatory signature mediates FGF2-induced angiogenesis. J Cell Mol Med 13:2083–2108

    Article  PubMed  Google Scholar 

  35. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H (1994) Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell 5:989–1001

    PubMed  CAS  Google Scholar 

  36. Choi HJ, Fukui M, Zhu BT (2012) Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. PLoS One 6:e24312

    Article  Google Scholar 

  37. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413–450

    Article  PubMed  CAS  Google Scholar 

  38. Lu H, Murtagh J, Schwartz EL (2006) The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 69:1207–1215

    Article  PubMed  CAS  Google Scholar 

  39. Murtagh J, Lu H, Schwartz EL (2006) Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res 66:8192–8199

    Article  PubMed  CAS  Google Scholar 

  40. Qin L, Zhang M (2010) Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J Biol Chem 285:32360–32369

    Article  PubMed  CAS  Google Scholar 

  41. Dalyot-Herman N, Delgado-Lopez F, Gewirtz DA, Gupton JT, Schwartz EL (2009) Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules. Biochem Pharmacol 78:1167–1177

    Article  PubMed  CAS  Google Scholar 

  42. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y (2007) A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 9:961–969

    Article  PubMed  CAS  Google Scholar 

  43. Presta M, Andrés G, Leali D, Dell’Era P, Ronca R (2009) Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 20:39–50

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Laboratorio di Oncoematologia, Dipartimento di Salute della Donna e del Bambino, Università di Padova, Via Giustiniani 3, 35128, Padua, Italy

    Elena Porcù, Giampietro Viola, Roberta Bortolozzi, Luca Persano & Giuseppe Basso

  2. Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy

    Stefania Mitola, Roberto Ronca & Marco Presta

  3. Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100, Ferrara, Italy

    Romeo Romagnoli & Pier Giovanni Baraldi

Authors
  1. Elena Porcù
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giampietro Viola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberta Bortolozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luca Persano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefania Mitola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Ronca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marco Presta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Romeo Romagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pier Giovanni Baraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giuseppe Basso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giampietro Viola.

Additional information

Elena Porcù and Giampietro Viola: equal contribution.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Porcù, E., Viola, G., Bortolozzi, R. et al. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis 16, 647–662 (2013). https://doi.org/10.1007/s10456-013-9343-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-013-9343-z

Keywords

Search

Navigation